Tesamorelin research occupies a unique position among growth hormone-releasing hormone (GHRH) analogs: it is the only compound in this class to have received U.S. Food and Drug Administration (FDA) approval, granted in 2010 under the brand name Egrifta® for the reduction of excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy. This regulatory milestone, achieved through a robust Phase III clinical development program, provides an unusually strong evidence base from which to understand the compound’s pharmacology — while also establishing a validated human platform from which researchers have extended investigations into related metabolic conditions, particularly non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD).
This article reviews the molecular pharmacology of tesamorelin, the clinical evidence base underlying its FDA approval, and the active research landscape exploring its applications beyond the initial indication.
This content is for research purposes only. Tesamorelin is an FDA-approved pharmaceutical for a specific clinical indication; its use outside that indication requires physician oversight and regulatory compliance. This article does not constitute medical advice.
Molecular Design: Engineering Stability into GHRH
Endogenous GHRH (somatocrinin) is rapidly degraded in plasma by dipeptidyl peptidase IV (DPP-IV) and other proteases, yielding a plasma half-life of only 5–7 minutes after intravenous administration. This metabolic liability makes native GHRH impractical as a pharmaceutical.
Tesamorelin was engineered by Theratechnologies Inc. to address this limitation. The compound consists of the full-length 44-amino acid GHRH peptide with a trans-3-hexenoic acid moiety conjugated to its N-terminal tyrosine residue. This modification confers resistance to DPP-IV-mediated cleavage at the Tyr-Ala N-terminal dipeptide bond, substantially extending the plasma half-life relative to native GHRH while preserving full GHRH receptor binding affinity and signaling efficacy.
Tesamorelin binds to and activates the pituitary GHRH receptor (GHRH-R), a Gs-coupled GPCR expressed predominantly on somatotrophs, driving cAMP elevation, PKA activation, and pulsatile GH secretion. Like sermorelin, tesamorelin preserves the physiological pulsatile GH release pattern and maintains downstream IGF-1 feedback regulation — a pharmacological profile distinct from direct GH administration.
FDA Approval: Phase III Evidence in HIV Lipodystrophy
HIV-associated lipodystrophy — a metabolic syndrome characterized by peripheral fat wasting, central fat accumulation (particularly visceral adiposity), dyslipidemia, and insulin resistance — is a recognized complication of long-term antiretroviral therapy (ART). Visceral fat accumulation in this population is associated with increased cardiovascular risk, metabolic syndrome, and significant quality-of-life impairment.
Two pivotal Phase III randomized, double-blind, placebo-controlled trials formed the basis of tesamorelin’s FDA approval. Falutz et al. (PMID: 20101189) enrolled HIV-infected patients with excess abdominal fat and demonstrated that tesamorelin 2 mg subcutaneously once daily produced a mean reduction of approximately 15–18% in visceral adipose tissue area as measured by computed tomography (CT) at 26 weeks, compared to placebo. Visceral fat reduction was accompanied by improvements in trunk-to-limb fat ratio, lipid profiles (reduced triglycerides), and patient-reported body image scores. Importantly, no significant adverse changes in glucose metabolism were observed at the trial duration studied, a consideration given GH’s known insulin-antagonizing effects.
Stanley et al. (2014) extended this evidence base with a randomized clinical trial examining tesamorelin’s effects on both visceral fat and hepatic fat content in ART-treated HIV patients with abdominal fat accumulation (PMID: 25038357). Results demonstrated significant reductions in visceral adipose tissue (mean ~18%) alongside significant reductions in liver fat fraction measured by magnetic resonance spectroscopy, providing early evidence linking tesamorelin’s lipolytic effects in the visceral compartment to hepatic triglyceride reductions.
Mechanism of Visceral Fat Reduction
The mechanistic pathway linking GHRH-R activation to preferential visceral fat loss is understood through the biology of GH signaling in adipose tissue. GH receptors are expressed across adipose depots, but visceral adipocytes are uniquely sensitive to GH-stimulated lipolysis due to their higher receptor density, higher portal insulin exposure (which sensitizes them to GH counter-regulatory effects), and greater density of beta-adrenergic receptors that work in concert with GH to mobilize stored triglycerides.
GH stimulates lipolysis by activating hormone-sensitive lipase (HSL) and inhibiting lipoprotein lipase (LPL) in adipocytes. In the visceral compartment specifically, GH’s insulin-antagonizing effects disinhibit HSL activity that was suppressed by the hyperinsulinemia common in lipodystrophic HIV patients. The resulting free fatty acid (FFA) efflux from visceral fat reduces portal FFA delivery to the liver — an upstream driver of hepatic steatosis — providing a mechanistic link between tesamorelin’s visceral fat effects and its liver fat-reducing properties.
Additionally, GH directly suppresses de novo lipogenesis in the liver by downregulating sterol regulatory element-binding protein-1c (SREBP-1c) target genes, further reducing hepatic triglyceride accumulation independent of peripheral lipolysis effects.
Tesamorelin Research and NAFLD: Emerging Research
The connection between visceral fat reduction and hepatic steatosis improvement, first noted in the 2014 Stanley trial, prompted a dedicated clinical investigation into tesamorelin’s utility for HIV-associated NAFLD — a population with particularly high NAFLD prevalence and aggressive disease progression.
Stanley et al. (2019) reported results from a randomized, double-blind, multicenter trial (PMID: 31611038) in which HIV-infected individuals with confirmed NAFLD on liver biopsy were randomized to tesamorelin or placebo for 12 months. The primary endpoint — reduction in liver fat fraction by MRI-PDFF — was met, with tesamorelin reducing liver fat by a significantly greater magnitude than placebo. Secondary analyses suggested favorable effects on liver histology scores, including the NAFLD Activity Score (NAS), and reductions in liver fibrosis markers in a subset of participants.
Fourman et al. (2020) investigated the molecular underpinnings of these effects through hepatic transcriptomic analysis of liver biopsy samples (PMID: 32701508). GH-regulated gene expression signatures were enriched in tesamorelin-treated subjects, with upregulation of genes involved in fatty acid oxidation and downregulation of lipogenic pathways — findings consistent with the mechanistic model described above and providing molecular-level evidence for GH-driven hepatic metabolic reprogramming.
This NAFLD research thread has attracted interest from investigators studying metabolic liver disease in non-HIV populations, though direct evidence of tesamorelin efficacy in non-HIV MASLD populations remains limited and is an active area of investigation.
Safety Profile and Research Considerations
The Phase III clinical trial database for tesamorelin provides a well-characterized safety profile. Common adverse effects include injection site reactions, fluid retention (consistent with GH’s mineralocorticoid-like effects), arthralgia, and myalgia. GH-mediated insulin resistance is a theoretical concern; trials documented modest increases in fasting glucose in some subjects, though progression to frank diabetes was not significantly increased versus placebo in short-to-medium term follow-up.
Immunogenicity was observed in a subset of subjects, with development of anti-tesamorelin IgG antibodies in approximately 50–70% of treated participants in longer studies. Cross-reactivity with endogenous GHRH antibodies occurred in roughly 60% of antibody-positive subjects; however, antibody status did not appear to attenuate the visceral fat reduction efficacy meaningfully, suggesting that neutralizing antibody titers were insufficient to ablate pharmacological activity in most cases.
Compound Information
Tesamorelin is available from Rejuven8 Peptides for qualified preclinical research applications.
All products are supplied for laboratory and research use only. Not for human consumption.
References
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Clin Endocrinol Metab. 2010;95(9):4291–4304. PMID:20101189
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. PMID:25038357
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830. PMID:31611038
- Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(15):e140134. PMID:32701508
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. PMID:18057339
- Tesamorelin, liver fat, and NAFLD in the setting of HIV. Lancet HIV. 2019;6(12):e804–e805. PMID:31611037
- Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300(5):509–519. PMID:18677023
Research Use Disclaimer: This content is provided for educational and scientific research purposes only. Tesamorelin supplied by Rejuven8 Peptides is intended exclusively for in vitro and preclinical laboratory research. It is not intended for human or veterinary therapeutic use, self-administration, or general wellness applications. Nothing in this article constitutes medical advice. Researchers should comply with all applicable local regulations governing research peptide procurement and use.
All products are sold for research purposes only. Not for human consumption. These statements have not been evaluated by the FDA. This content is for informational and educational purposes only and does not constitute medical advice.
